Navigation Links
Michael J. Fox Foundation Commits Up to $3 Million for Clinical Trials That Can Improve Treatment of Parkinson's Disease
Date:2/26/2008

NEW YORK, Feb. 26 /PRNewswire-USNewswire/ --- In the interest of accelerating delivery of transformative treatments for Parkinson's disease, The Michael J. Fox Foundation for Parkinson's Research today announced the 2008 launch of its annual Clinical Intervention Awards. The program, formerly known as Clinical Discovery Awards, has been revamped with an even greater focus on clinical testing of promising therapies with potential to fundamentally improve the treatment of Parkinson's disease symptoms and even impact disease progression.

"Trials to develop transformative treatments are not only scientifically and technically challenging but are often hampered by budgetary constraints that can limit the quality and quantity of data collected and therefore the interpretability of results," said Katie Hood, CEO of The Michael J. Fox Foundation. "Clinical Intervention is designed to accelerate the development of transformative treatments by strategically allocating resources to address this challenge, and ultimately to increase the number of therapies progressing through the clinical trial pipeline."

Ideal proposals will be rooted in well-designed and rigorous clinical trials that test potentially high-impact treatment approaches. Applicants may seek full support for a trial, if feasible within the program budgetary constraints, or may request funding to supplement a clinical testing effort supported by other funding sources. In the latter case, MJFF is particularly interested in assisting sponsors wishing to maximize data collected from clinical trials by the inclusion of additional trial features (e.g., increased sample size, inclusion/testing of additional or novel endpoints, increasing frequency of subject assessments or trial duration, etc.). Applicants should make a strong case for how the additional information can significantly improve the overall trial and lead to better decision making regarding continued clinical development of the tested therapeutic approach.

The program is open to academic and industry investigators alike and will provide up to $3 million in funding for clinical research projects for up to three years. Pre-proposals will be reviewed by the Foundation's scientific staff and a panel of scientific experts and must be submitted online by April 14, 2008. Information about submitting pre-proposals online can be found on the Foundation's Web site (http://www.michaeljfox.org). Applicants whose pre-proposals are determined to meet the review criteria will be invited to submit full application proposals. Funding is anticipated by September 2008.

A conference call with MJFF Research Programs staff to further clarify the aims and goals of this initiative will be held March 11 at 12 p.m. U.S. Eastern Time. Researchers wishing to participate in the call must RSVP to conferencecalls@michaeljfox.org and will receive an e-mail reply with call-in details.

About The Michael J. Fox Foundation

Founded in 2000, The Michael J. Fox Foundation for Parkinson's Research is dedicated to ensuring the development of a cure for Parkinson's disease within this decade through an aggressively funded research agenda. The Foundation has funded over $115 million in research to date.


'/>"/>
SOURCE Michael J. Fox Foundation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Michael J. Fox Foundation Awards Up to $3 Million to Industry Teams to Jumpstart Promising PD Drug Development
2. Kevin McHale Instrumental in Forming the Help Me Hear Foundation
3. AIDS Healthcare Foundation Names Homayoon Khanlou, M.D. as its Chief of Medicine, U.S.
4. CellCyte Genetics Corp. Enters Collaborative Research Agreement With Cleveland Clinic Foundation to Qualify Stem Cell Delivery in Damaged Heart Tissue
5. Nobel Prize Awarded to Foundation for Biomedical Research Board Member
6. The Oral Cancer Foundation Urges HPV Vaccination for Males
7. MedicAlert Foundation Joins The Alzheimers Association to Offer MedicAlert(R) + Alzheimers Association Safe Return(R) - Live 24-Hour Emergency Response for Wandering and Medical Emergencies
8. Phase 1 & 2 Data of Perifosine (KRX-0401) in Patients with Advanced Renal Cell Carcinoma Presented Today at the 25th Annual Chemotherapy Foundation Symposium
9. Grantees of the Avon Foundation Breast Cancer Prevention Research Initiative Gather in Houston to Report Interim Findings
10. Five Clinical Studies to Receive $2.5 Million Under Foundations 2007 Clinical Discovery Program
11. Alpha-1 Foundation, AARC Cooperate on Study to Test 5,000 COPD Patients for Alpha-1
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... 2017  Axium Pharmaceuticals Inc., the creator of the drug Truveta ... beginning stages of an IPO. The United States ... average cost of a prescription epilepsy drug being $450.00-$1200.00 for a one ... AXIUM PHARMACEUTICALS, INC ... Another staggering figure is the fact that Americans spent $42 billion ...
(Date:8/14/2017)... and PETACH TIKVAH, Israel ... (NASDAQ: BCLI), a leading developer of adult stem cell ... second quarter ending June 30, 2017. ... of preparing for our pivotal Phase 3 trial to ... Lebovits , President and Chief Executive Officer of BrainStorm. ...
(Date:8/8/2017)... 2017  BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical ... financial results for the second quarter ended June 30, ... quarter 2017 and to date: ... for the Company,s lead project, BL-8040: ... BL-8040 as novel stem cell mobilization treatment for autologous ...
Breaking Medicine Technology:
(Date:8/19/2017)... Texas (PRWEB) , ... August 19, 2017 , ... ... with contemporary illustrations of breastfeeding mothers. These illustrations show the diversity ... available in prints in a wide range of sizes. These illustrations are also ...
(Date:8/19/2017)... ... ... “Congratulations! It's A Boy! God’s Gift: A Story of Love”: a children’s book ... A Boy! God’s Gift: A Story of Love” is the creation of published authors, ... by Christian Faith Publishing, Dale Anthony and Rachael Anthony’s new book is a perfect ...
(Date:8/18/2017)... ... August 18, 2017 , ... ... (“Quick”), a highly specialized asset-light logistics provider of complex transport solutions for ... agreement to purchase Unitrans International Corporation, a division of Roadrunner Transportation Systems, ...
(Date:8/18/2017)... ... August 18, 2017 , ... As an industry leader, ... webinar, they will present the line of epMotion automated liquid handling system. This ... can automate everyday pipetting tasks. , Ideal for scientists and lab technicians with ...
(Date:8/18/2017)... TX (PRWEB) , ... August 18, 2017 , ... ... assistance and financial planning services to communities in east Texas, is launching a ... Brain Tumor Foundation. , Founded in 1991, the Pediatric Brain Tumor Foundation (PBTF) ...
Breaking Medicine News(10 mins):